Experts discuss current and investigational antibody drug conjugates (ADCs) in non-small cell lung cancer treatment and how they affect therapy approaches.
July 13th 2022
Edward S. Kim, MD, MBA, and Alexander Spira, MD, PhD, FACP, provide an overview of antibody-drug conjugates, including mechanism of action, historical milestones in development, and the approved ADCs for non–small cell lung cancer treatment.
July 21st 2022
Alexander Spira, MD, PhD, FACP, and Edward S. Kim, MD, MBA, shift their focus to the use of antibody-drug conjugates in non-small cell lung cancer treatment with a review of ADC clinical trial data.
August 2nd 2022
A discussion on how ADCs affect current standards of care in the non-small cell lung cancer treatment landscape.
August 8th 2022
Drs Edward S. Kim and Alexander Spira answer viewer questions on ADCs in non-small cell lung cancer.